Lakefront Biotherapeutics NV
ENXTAMLKFT cost to borrow surges to 5.2% — up 239% in one week as availability plummets to 2,387%.
Snapshot as of 22 Jun 2026
Galapagos NV headed into today's Q1 print as a stock that has spent months in a quiet holding pattern — and the numbers that landed yesterday evening confirmed why the market has been reluctant to move decisively in…
Galapagos NV dropped its Q1 2026 results after market close on May 6, delivering a split verdict that keeps the debate around this Belgian biotech very much alive. The headline read was mixed. Q1 EPS came in at $0.25,…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LKFT — free to start on ORTEX.
Sign up for free →Open LKFT on ORTEX